RKDA 10-Q: SEC filing
Arcadia Biosciences
Filed with the SEC on · accession 0001193125-26-458412
RKDA filed a 10-Q (quarterly report) with the SEC on Nov 12, 2026. The quarterly report: unaudited results for the quarter plus management’s comments.
Summary of the filing
Arcadia Biosciences filed its Q3 2026 Form 10-Q, reporting quarterly financial results and disclosing details of its June 2026 private placement of pre-funded warrants and Series A-1/A-2 investment options, along with related placement agent options and warrant modifications.
Key details
✦ Ask GOAX AI about this filing — what it means for RKDA, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for RKDA?
Click hereFrequently asked questions
What did RKDA file with the SEC on Nov 12, 2026?
RKDA filed a 10-Q (SEC filing). Arcadia Biosciences filed its Q3 2026 Form 10-Q, reporting quarterly financial results and disclosing details of its June 2026 private placement of pre-funded warrants and Series A-1/A-2 investment options, along with related placement agent options and warrant modifications.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
Other RKDA SEC filings
Get alerts when RKDA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days